Results 21 to 30 of about 6,285 (202)

Can levosimendan reduce ECMO weaning failure in cardiogenic shock?: a cohort study with propensity score analysis

open access: yesCritical Care, 2020
Background Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has been increasingly used over the last decade in patients with refractory cardiogenic shock.
Enrique Guilherme   +5 more
doaj   +1 more source

Impact of levosimendan on efficacy and renal function in acute heart failure according to renal function: A perspective, multi-center, real-world registry

open access: yesFrontiers in Cardiovascular Medicine, 2022
ObjectiveAcute heart failure (AHF) is associated with high mortality. Levosimendan, an inodilator, has proved to increase cardiac output and exert renoprotective effect in AHF.
Han Zhang   +7 more
doaj   +1 more source

Single-center experience with levosimendan in children undergoing cardiac surgery and in children with decompensated heart failure

open access: yesBMC Anesthesiology, 2011
Background Levosimendan has pharmacologic and hemodynamic advantages over conventional intravenous inotropic agents. It has been used mainly as a rescue drug in the pediatric intensive care unit or in the operating room.
Suominen Pertti K
doaj   +1 more source

Levosimendan vs. Milrinone: Early Renal and Hemodynamic Outcomes after lnfant Cardiac Surgery [PDF]

open access: yes, 2022
Background: Myocardial and renal dysfunction are common after cardiac surgery in young children, which increases risk of complications and delayed recovery.
Thorlacius, Elin M
core   +1 more source

Levosimendan reduces segmental pulmonary vascular resistance in isolated perfused rat lungs and relaxes human pulmonary vessels.

open access: yesPLoS ONE, 2020
INTRODUCTION:Levosimendan is approved for acute heart failure. Within this context, pulmonary hypertension represents a frequent co-morbidity. Hence, the effects of levosimendan on segmental pulmonary vascular resistance (PVR) are relevant.
Annette Dorothea Rieg   +12 more
doaj   +1 more source

Sotatercept Rescue Therapy for Acute Right Heart Failure in HIV-Associated PAH. [PDF]

open access: yesPulm Circ
ABSTRACT Despite major advances in antiretroviral treatment, pulmonary arterial hypertension (PAH) remains a common, severe complication in patients diagnosed with HIV. Treatment of HIV‐associated PAH targets the nitric oxide, endothelin, and prostacyclin pathways, with limited evidence for novel therapies, as these patients have been excluded from ...
Li Y   +8 more
europepmc   +2 more sources

Treatment with levosimendan in an experimental model of early ventilator-induced diaphragmatic dysfunction

open access: yesDrug Target Insights, 2023
Introduction: Mechanical ventilation (MV) is a life-saving approach in critically ill patients. However, it may affect the diaphragmatic structure and function, beyond the lungs.
Vanessa Zambelli   +6 more
doaj   +1 more source

Perioperative Use of Levosimendan in Patients with Impaired Right Ventricular Function Undergoing Cardiac Surgery with Cardiopulmonary Bypass A Randomized Controlled Study [PDF]

open access: yesAin Shams Medical Journal
Background: The purpose of this study is to investigate the impact of levosimendan on right ventricular (RV) function in patients with reduced RV function after open heart surgery with cardiopulmonary bypass (CBP).
Mohamed Alhadidy   +3 more
doaj   +1 more source

Use of levosimendan in hemodynamic management of heart failure in two neonates with intracranial arteriovenous shunts: a case series

open access: yesItalian Journal of Pediatrics, 2023
Background The hemodynamic status of newborns with intracranial arteriovenous shunts (AVSs) may be extremely complex. Mini-invasive hemodynamic monitoring through innovative techniques such as Near-Infrared Spectroscopy (NIRS) and Pressure Recording ...
Francesca Landolfo   +12 more
doaj   +1 more source

Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap [PDF]

open access: yes, 2021
Nicolina Conti,1 Milo Gatti,2,3 Emanuel Raschi,2 Igor Diemberger,1,4 Luciano Potena4 1Cardiology Unit, Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum - University of Bologna, Bologna, Italy; 2Pharmacology Unit ...
Conti N.   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy